BR112021021663A2 - Inibidores da via rank em combinação com inibidores de cdk - Google Patents

Inibidores da via rank em combinação com inibidores de cdk

Info

Publication number
BR112021021663A2
BR112021021663A2 BR112021021663A BR112021021663A BR112021021663A2 BR 112021021663 A2 BR112021021663 A2 BR 112021021663A2 BR 112021021663 A BR112021021663 A BR 112021021663A BR 112021021663 A BR112021021663 A BR 112021021663A BR 112021021663 A2 BR112021021663 A2 BR 112021021663A2
Authority
BR
Brazil
Prior art keywords
inhibitors
combination
cdk
rank pathway
methods
Prior art date
Application number
BR112021021663A
Other languages
English (en)
Portuguese (pt)
Inventor
António Marques Da Costa Luis
Cristina Cara De Anjo Casimiro Sandra
Original Assignee
Inst De Medicina Molecular Joao Lobo Antunes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst De Medicina Molecular Joao Lobo Antunes filed Critical Inst De Medicina Molecular Joao Lobo Antunes
Publication of BR112021021663A2 publication Critical patent/BR112021021663A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112021021663A 2019-04-30 2020-04-24 Inibidores da via rank em combinação com inibidores de cdk BR112021021663A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840810P 2019-04-30 2019-04-30
PT11548319 2019-04-30
PCT/PT2020/050017 WO2020222668A1 (en) 2019-04-30 2020-04-24 Rank pathway inhibitors in combination with cdk inhibitors

Publications (1)

Publication Number Publication Date
BR112021021663A2 true BR112021021663A2 (pt) 2022-05-17

Family

ID=70775461

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021663A BR112021021663A2 (pt) 2019-04-30 2020-04-24 Inibidores da via rank em combinação com inibidores de cdk

Country Status (9)

Country Link
US (1) US20220195059A1 (https=)
EP (1) EP3962945A1 (https=)
JP (1) JP2022530241A (https=)
KR (1) KR20220002316A (https=)
AU (1) AU2020266083A1 (https=)
BR (1) BR112021021663A2 (https=)
CA (1) CA3132656A1 (https=)
MX (1) MX2021013271A (https=)
WO (1) WO2020222668A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022272427A1 (en) * 2021-05-12 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN115718192B (zh) * 2022-11-25 2025-02-14 浙江洛兮医疗科技有限公司 一种免疫组化即用型pd-l1抗体试剂
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581916A (en) 1897-05-04 Harvester
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
NZ235329A (en) 1989-09-15 1992-01-29 Res Triangle Inst 20(s or rs)-camptothecin derivatives and pharmaceutical compositions
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
CA2346866A1 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Combination therapy with vip antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
PL369742A1 (en) 2001-10-15 2005-05-02 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
NZ535232A (en) 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
US6818663B2 (en) 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
WO2004069137A2 (de) 2003-02-07 2004-08-19 Ge Bayer Silicones Gmbh & Co. Kg Verwendung von polyamino- und/oder polyammonium-polysiloxancopolymeren
WO2004097048A1 (en) 2003-04-28 2004-11-11 Canon Kabushiki Kaisha Process for assay of nucleic acid by competitive hybridization using a dna microarray
NZ580700A (en) 2007-04-19 2012-01-12 Dong A Pharm Co Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
US11596642B2 (en) * 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
US20200129473A1 (en) * 2017-07-21 2020-04-30 Eisai R&D Management Co., Ltd. Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
WO2020222668A1 (en) 2020-11-05
JP2022530241A (ja) 2022-06-28
AU2020266083A1 (en) 2021-09-23
MX2021013271A (es) 2022-01-06
US20220195059A1 (en) 2022-06-23
EP3962945A1 (en) 2022-03-09
CA3132656A1 (en) 2020-11-05
KR20220002316A (ko) 2022-01-06

Similar Documents

Publication Publication Date Title
BR112021021663A2 (pt) Inibidores da via rank em combinação com inibidores de cdk
BR112021019722A2 (pt) Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico
Xiao et al. Metformin promotes innate immunity through a conserved PMK-1/p38 MAPK pathway
Krifka et al. A review of adaptive mechanisms in cell responses towards oxidative stress caused by dental resin monomers
BR112022022401A2 (pt) Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade
EA200900927A1 (ru) Способы определения устойчивости рака к ингибиторам гистондеацетилазы
JOP20200050A1 (ar) عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام
EA201991985A1 (ru) Конъюгаты антитело-лекарственное средство (калс) на основе ингибиторов гдац и применение в терапии
PH12019502594A1 (en) Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
BR112014026088A2 (pt) produto de tratamento de tecidos, estojo, método de fabricação de um produto de tratamento de tecidos, método de tratamento, e uso do produto de tratamento de tecidos
BR112023022481A2 (pt) Métodos de tratamento de cânceres com mutação de perda de função bialélica ou de superexpressão gênica
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112018012022A2 (pt) ?composição, e, método para tratamento ou redução do risco de colestase intra-hepática?
BR112022001341A2 (pt) Inibidores de enzima
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase
BR112019011365A2 (pt) métodos para tratar câncer
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
Malyarenko et al. Radiosensitizing effect of the fucoidan from brown alga Fucus evanescens and its derivative in human cancer cells
Park et al. Oral administration of glycine and leucine dipeptides improves skin hydration and elasticity in UVB-irradiated hairless mice
BR112016007592A2 (pt) proteína de ligação biespecífica que se liga a pelo menos dois alvos, conjugado de proteína de ligação biespecífica, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, método para produzir uma proteína de ligação biespecífica, método para determinar a reatividade de um paciente a um agente terapêutico que tem capacidade para modular a atividade de um tlr, método para ativar ou inibir células responsivas a tlr9, método para tratar um paciente que precisa de ativação de tlr9 ou inibição de tlr e método para identificar um inibidor ou estimulador de sinalização de tlr
MX2017004662A (es) Composiciones y metodos para mejorar la movilidad o actividad o tratar la fragilidad.
BR112021024997A2 (pt) Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso
Qin et al. Protective effect of Sirt1 against radiation-induced damage

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2824 DE 18/02/2025.